Yahoo Web Search

Search results

1. • 

     Drug targeting clear cell renal cell carcinoma shows promising approach

     Newswise· 3 days ago

     April 23, 2024 – In a groundbreaking phase one clinical trial led by UT Southwestern Medical Center,...

2. • 

     Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales

     Zacks via Yahoo Finance· 3 hours ago

     Keytruda, the biggest product in Merck’s portfolio, generated sales of $6.95 billion in the quarter,...

3. • 

     Moriah Elyse Kerns - Valencia County News-Bulletin

     Valencia County News-Bulletin· 7 hours ago

     Moriah Elyse Kerns, age 27, a resident of Los Lunas, passed away on April 20, 2024, as a result of renal cell carcinoma. Moriah was pursuing ...

4. • Signs and Symptoms of Kidney Cancer

     Health via Yahoo News· 7 days ago

     In fact, kidney cancer is often found accidentally during a routine physical or imaging exam, such as an X-ray or MRI. There are three main types of kidney cancers: renal ...

5. • 

     Merck beats earnings forecasts as cancer drug sales boom

     Crain's New York Business· 3 hours ago

     The guidance comes as Merck’s first-quarter earnings topped $15.8 billion, a 9% increase from the...

6. • 

     Merck highlights progress on HIV, hypertension, cervical cancer drugs

     WFMZ Eastern Pennsylvania and Western New Jersey· 2 hours ago

     Merck got off to an excellent start in the first quarter of 2024. Wall Street met the news with...

7. • 

     Analysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?

     Investor's Business Daily· 1 day ago

     Patients will receive Keytruda or Keytruda plus the vaccine after bladder or kidney removal. Bladder...

8. • Cancer drug trial provides lessons for future

     Medical Xpress· 2 hours ago

     A cancer drug was found to be ineffective in preventing recurrence of kidney cancer in patients who recently underwent tumor removal surgery, according to a clinical trial published in the Journal ...

9. • Innovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting

     WKBN 27 Youngstown· 17 hours ago

     First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced colorectal cancer: Safety and efficacy results from a phase I study. First-in-class PD-1/IL-2 bispecific ...

10. • 

      How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?

      Zacks via Yahoo Finance· 3 days ago

      Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine,...